Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 24.25
Bid: 24.00
Ask: 24.50
Change: 0.00 (0.00%)
Spread: 0.50 (2.083%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 24.25
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: Cyan, Aer Lingus, Mobile Tornado ...

Thu, 07th Jun 2012 13:59

Cyan Holdings, the wireless solutions company, has revealed that three more Cyan partners have received requests from the Tamil Nadu Electricity Board (TNEB) Automatic Meter Reading tender to proceed with installation and commissioning of 500 unit pilots within the next 25 days. The news follows Cyan's announcement at the end of May that the first Cyan metering partner in India had received a formal request from the TNEB. Airline company Aer Lingus Group has said that its flown passenger load factor in May 2012 increased by 2.9 percentage points on May 2011 to 76.2%. Short haul flown load factor was 73.8%, an increase of 0.9 points on May 2011, with capacity decreasing by 1.6%. Long haul flown load factor was 81.5%, a year-on-year (y/y) increase of 7.4 points, with capacity increasing by 0.5%. The company's flown passengers in May totalled 882,000, a y/y increase of 0.1% compared. Short haul flown passengers in May 2012 were 793,000, a y/y decrease of 1.1%, while long haul flown passengers in May 2012 were 89,000, an increase of 12.7% on May 2011. Aer Lingus Regional's total flown passenger numbers in May 2012 were 88,000, an increase of 33.3% compared to May 2011. Mobile Tornado Group, a provider of instant communication mobile applications to the enterprise market, posted a rise in revenues from £1.4m to £2.0m, while pre-tax loses narrowed to £1.2m (2010: £1.6m). The cost of sales doubled to £0.7m, while basic and diluted losses per share came in at 0.59p, compared to 0.85p the previous year. The company achieved increased sales activity during the year, up 43%, and believes that market within which it operates is increasingly receptive to the proposition it has developed. ANGLE, a technology commercialisation company, has said that its partner, ORIGIO, has received a bid from Cooper Companies, which values ORIGIO at $189m, including debt. Directors and shareholders owning a total of 46% in the company have signed irrevocable undertakings to accept the Cooper offer. The offer represents a 73% premium to the closing price of the shares on June 1st. Cooper has said the combined business will be ranked number one in the IVF market with a 39% market share. If the offer is completed, ORIGIO will continue under the same executive management team and name, operating as an indirect wholly-owned subsidiary of Cooper.Sareum Holdings has conditionally raised £25,000 (before expenses) after placing just over 2.9m shares at 0.85p each. The placing follows a placing made on Wednesday, which raised £0.23m. The company believes that both placings offer the most effective way of providing capital to accelerate its drug discovery programme and to provide working capital for the company. It is expected that the shares will begin trading on June 11th. The company now has around 1.5bn shares in issue.
More News
31 May 2018 12:17

Sareum Regains Worldwide Rights To Leukaemia Treatment

LONDON (Alliance News) - Sareum Holdings PLC said on Thursday that it has regained its worldwide rights to a potential treatment for leukaemia and other blood-related cancers.The drug said

Read more
15 Mar 2018 13:55

Sareum Partner Sierra Oncology To Present Positive SRA737 Results

LONDON (Alliance News) - Sareum Holdings PLC said Thursday its development partner Sierra Oncology's SRA737 results have been accepted for presentation at the annual of of

Read more
9 Jan 2017 16:39

Sareum Holdings receives milestone payment

(ShareCast News) - Sareum Holdings, an AIM listed specialist cancer drug discovery and development company, has announced the attainment of a $2m milestone payment as part of the Chk1 license agreement between its co-investment partner the CRT Pioneer Fund and Sierra Oncology, formerly known as ProN

Read more
9 Jan 2017 12:19

Sareum To Receive USD550,000 From Joint Licence Success Payment

Read more
24 Oct 2016 15:02

Sareum reports positive results from TYK2 programme

(ShareCast News) - Specialist cancer drug discovery and development business Sareum announced a successful conclusion from its feasibility study into the potential for its TYK2 programme lead molecules to treat T-Cell Acute Lymphoblastic Leukaemia (T-ALL) on Monday. The AIM-traded company said the i

Read more
24 Oct 2016 08:13

Sareum Welcomes Positive Feasibility Results For Leukemia Treatment

Read more
17 Oct 2016 14:16

Sareum Holdings granted patents in Japan and Singapore

(ShareCast News) - Specialist cancer drug discovery and development company Sareum announced on Monday that the Japan and Singapore Patent Offices have issued notifications that patents will be granted for inventions associated with its Aurora+FLT3 kinase inhibitor programme. The AIM-traded firm sai

Read more
27 Sep 2016 11:13

Sareum Holdings Co-Investment Partner Inks Licence Agreement

Read more
3 Aug 2016 14:56

Sareum programme receives patents in Hong Kong and China

(ShareCast News) - Specialist cancer drug discovery and development business Sareum announced on Wednesday that the Chinese Patent Office and the Hong Kong Patents Registry have issued notifications that patents will be granted for inventions associated with the company's Aurora+FLT3 Kinase Inhibito

Read more
23 May 2016 11:06

Sareum Holdings Says Phase I CCT245737 Trials To Open End Of May

Read more
23 May 2016 11:01

*Sareum Holdings Says Phase I CCT245737 Trials To Open End Of May

Read more
17 May 2016 08:03

Sareum Appoints Silence Therapeutics' Stephen Parker As Chairman

Read more
5 Apr 2016 12:33

Sareum cancer drug candidate gets MHRA trial approval

(ShareCast News) - Sareum Holdings was pressing ahead with one of its cancer drug programmes on Tuesday, having received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for the Clinical Trial Applications submitted for CHK1 inhibitor drug candidate CCT245737. The AIM-tra

Read more
5 Apr 2016 09:46

Sareum Holdings Gets Clinical Trial Approval For Cancer Drug Candidate

Read more
24 Mar 2016 12:03

Sareum Raises GBP1.1 Million For Drug Development Programmes (ALLISS)

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.